Also trades as: 0I0X.L (LSE) · $vol 0M
CDXS NASDAQ
Codexis, Inc.
1W: +3.0%
1M: -8.1%
3M: -48.9%
YTD: -15.5%
1Y: -45.6%
3Y: -12.3%
5Y: -94.7%
$1.36
+0.00 (+0.00%)
Weekly Expected Move ±5.5%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
BlackRock Inc. Makes New Investment in Codexis, Inc. $CDXS
Codexis to Participate in Cantor Global Healthcare Conference 2026
Codexis (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis outlines $72M-$76M 2026 revenue as it plans ~$25M GMP facility build-out
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis Reports Second Quarter 2026 Financial Results
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
Codexis falls 20% after pricing $25M stock offering at $1.50/share
12 Health Care Stocks Moving In Thursday's After-Market Session
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis (CDXS) Q1 2026 Earnings Transcript
Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis Reports First Quarter 2026 Financial Results
Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis to share RNA manufacturing advances at TIDES USA
Codexis to Report First Quarter 2026 Financial Results on May 7
Aberdeen Group plc Raises Stake in Codexis, Inc. $CDXS
Assenagon Asset Management S.A. Increases Stock Holdings in Codexis, Inc. $CDXS
Tudor Investment Corp ET AL Invests $1.31 Million in Codexis, Inc. $CDXS
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results
Dow Tumbles Over 1%; US Weekly Jobless Claims Fall
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Codexis rises after Q4 beat, strong outlook
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis outlines $72M–$76M 2026 revenue target as ECO Synthesis gains momentum and CDMO partnerships expand
Codexis (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
12 Health Care Stocks Moving In Wednesday's After-Market Session
Codexis GAAP EPS of $0.11 beats by $0.14, revenue of $38.9M beats by $3.07M
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Here are the major earnings after the close Wednesday
Earnings Scheduled For March 11, 2026
Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Codexis Achieves ISO 9001:2015 Certification
Codexis, Inc. $CDXS Shares Sold by Federated Hermes Inc.
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics